<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Prevention of ovarian hyperstimulation syndrome</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Prevention of ovarian hyperstimulation syndrome</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Prevention of ovarian hyperstimulation syndrome</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Cristiano E Busso, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sérgio Reis Soares, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Antonio Pellicer, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert L Barbieri, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kathryn A Martin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 28, 2020.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1230402"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Ovarian hyperstimulation syndrome (OHSS) is the most serious complication of controlled ovarian hyperstimulation (COH) for assisted reproduction technologies (ART). It is characterized by a broad spectrum of signs and symptoms that includes abdominal distention and discomfort, enlarged ovaries, ascites, and other complications of enhanced vascular permeability. The syndrome can be strictly defined as the shift of serum from the intravascular space to the third space, mainly to the abdominal cavity, in the context of enlarged ovaries due to follicular stimulation. In its very severe form, OHSS is a life-threatening condition.</p><p>The prevention of OHSS will be reviewed here. The pathogenesis, clinical manifestations, and management of established OHSS are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7401.html" rel="external">"Pathogenesis, clinical manifestations, and diagnosis of ovarian hyperstimulation syndrome"</a> and  <a class="medical medical_review" href="/z/d/html/101383.html" rel="external">"Management of ovarian hyperstimulation syndrome"</a>.)</p><p class="headingAnchor" id="H1210635446"><span class="h1">BACKGROUND</span><span class="headingEndMark"> — </span>Ovarian hyperstimulation syndrome (OHSS) is the most serious complication of controlled ovarian hyperstimulation (COH) for assisted reproduction technologies (ART). It is a broad spectrum of signs and symptoms that include abdominal distention and discomfort, enlarged ovaries, ascites, and other complications of enhanced vascular permeability [<a href="#rid1">1,2</a>]. OHSS is an iatrogenic and potentially life-threatening condition that affects young, healthy women. In addition, there is an important economic burden associated with OHSS due to absence from work, bed rest, or hospitalization and intensive medical management of severe cases.</p><p>The pathophysiology of OHSS is not fully understood, but increased capillary permeability with the resulting loss of fluid into the third space is its main feature (see  <a class="medical medical_review" href="/z/d/html/7401.html" rel="external">"Pathogenesis, clinical manifestations, and diagnosis of ovarian hyperstimulation syndrome"</a>). In the susceptible patient, human chorionic gonadotropin (hCG) administration for final follicular maturation and triggering of ovulation is the pivotal stimulus for OHSS, leading to overexpression of vascular endothelial growth factor (VEGF) in the ovary, release of vasoactive-angiogenic substances, increased vascular permeability, loss of fluid to the third space, and full-blown OHSS  (<a class="graphic graphic_algorithm graphicRef66510" href="/z/d/graphic/66510.html" rel="external">algorithm 1</a>).</p><p>There are two clinical forms of OHSS, both hCG related: the <strong>early-onset</strong> form (occurring in the first eight days after hCG administration) and the <strong>late-onset</strong> form (occurring nine or more days after hCG administration, related to pregnancy-induced hCG production) [<a href="#rid3">3</a>]. (See  <a class="medical medical_review" href="/z/d/html/7401.html" rel="external">"Pathogenesis, clinical manifestations, and diagnosis of ovarian hyperstimulation syndrome", section on 'Onset'</a>.)</p><p class="headingAnchor" id="H119223140"><span class="h1">PREVENTION OF OHSS</span><span class="headingEndMark"> — </span>Ovarian hyperstimulation syndrome (OHSS) remains a common complication among women undergoing assisted reproductive technologies (ART); reported frequencies are approximately 20 to 33 percent for mild cases, 3 to 6 percent for moderate cases, and 0.1 to 2 percent for severe cases [<a href="#rid4">4-6</a>]. (See  <a class="medical medical_review" href="/z/d/html/7401.html" rel="external">"Pathogenesis, clinical manifestations, and diagnosis of ovarian hyperstimulation syndrome", section on 'Epidemiology'</a>.)</p><p class="headingAnchor" id="H16017368"><span class="h2">Keys to prevention</span><span class="headingEndMark"> — </span>The keys to preventing OHSS are to identify the potential risk for the individual patient and to plan appropriate strategies to avoid its occurrence. The main steps include [<a href="#rid7">7</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Recognition of risk factors for OHSS (such as previous episode of OHSS or exuberant ovarian response to gonadotropins, and polycystic ovarian syndrome [PCOS]). (See  <a class="medical medical_review" href="/z/d/html/7401.html" rel="external">"Pathogenesis, clinical manifestations, and diagnosis of ovarian hyperstimulation syndrome", section on 'Risk factors'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Extensive clinical experience with drugs used for ovarian stimulation (for ovulation induction, but more importantly for assisted reproduction, as the ovarian stimulation protocols are more aggressive and OHSS is more common). (See <a class="local">'Ovarian stimulation protocol'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Use of individualized ovarian stimulation regimens for assisted reproduction, using the minimum dose and duration of gonadotropin therapy necessary to achieve the treatment goal (particularly in those at risk for OHSS). (See <a class="local">'Ovarian stimulation protocol'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Other interventions such as pretreatment with <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a> and addition of a gonadotropin-releasing hormone (GnRH) antagonist are suggested in women with PCOS, a high-risk group. (See <a class="local">'Pretreatment with metformin'</a> below and <a class="local">'Addition of GnRH agonist or antagonist'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Modifying treatment when indicators for increasing OHSS risk develop:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Serum estradiol (E2) concentration &gt;3500 pg/mL (12,850 pmol/L)</p><p class="bulletIndent2"><span class="glyph">•</span>Development of many intermediate-sized follicles (more than 20 follicles &gt;10 mm) [<a href="#rid8">8</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Withholding gonadotropin therapy while continuing pituitary suppression with a GnRH agonist or antagonist until serum E2 levels fall into a range acceptable for human chorionic gonadotropin (hCG) administration (coasting) if the risk for OHSS is high. (See <a class="local">'Coasting'</a> below and <a class="local">'Withholding hCG (cycle cancellation)'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Using an alternative to standard-dose hCG for final oocyte maturation (lower dose hCG or gonadotropin-releasing hormone [GnRH] agonist). (See <a class="local">'Ovulatory triggers'</a> below.)</p><p></p><p class="headingAnchor" id="H779501460"><span class="h2">Ovarian stimulation protocol</span></p><p class="headingAnchor" id="H119223161"><span class="h3">Gonadotropin dose and type</span><span class="headingEndMark"> — </span>We suggest the use of individualized ovarian stimulation regimens, using the minimum dose and duration of gonadotropin therapy necessary to achieve follicular development and pregnancy, while avoiding the risk of OHSS.</p><p>Gonadotropin doses correlate with OHSS severity as indicated by ovarian size and severity of ascites and pleural effusion [<a href="#rid9">9</a>]. Therefore, in patients at risk, the starting dose of gonadotropins should be decreased (to 100 to 150 international units) [<a href="#rid10">10</a>]. The current approach to ovarian stimulation emphasizes an approach to dosing based upon patient variables such as age, body mass index (BMI), baseline serum anti-müllerian hormone concentrations, antral follicle count, and previous ovarian response. This approach typically uses lower doses than fixed ovarian stimulation protocols.</p><p>A clinical trial based upon this approach reported that clinical pregnancy rates were similar with a standard and individualized approach, but that the cancellation and OHSS rates were lower with the individualized approach [<a href="#rid11">11</a>]. Of note, there is currently no consensus on the ideal dosing approach that optimizes pregnancy rates yet minimizes OHSS risk. (See  <a class="medical medical_review" href="/z/d/html/7404.html" rel="external">"In vitro fertilization: Overview of clinical issues and questions"</a>.)</p><p>In contrast to dose, the type of gonadotropin preparation (eg, <a class="drug drug_general" data-topicid="9607" href="/z/d/drug information/9607.html" rel="external">human menopausal gonadotropins</a> [hMG] versus recombinant follicle-stimulating hormone [rFSH] versus urinary follicle-stimulating hormone [uFSH]) does not appear to affect the risk of OHSS [<a href="#rid12">12-14</a>].</p><p class="headingAnchor" id="H119223168"><span class="h4">Monitoring</span><span class="headingEndMark"> — </span>We suggest monitoring patients using both transvaginal ultrasound (TVUS) (for follicular number and size) and serum E2 concentrations. Since multiple follicle development [<a href="#rid15">15</a>] and high E2 levels [<a href="#rid16">16</a>] are important risk factors, early detection of either helps prevent OHSS by withholding the ovulatory dose of hCG in high-risk cycles.</p><p>One meta-analysis of eight studies of women undergoing in vitro fertilization (IVF) concluded that TVUS alone was adequate for patient monitoring, as clinical pregnancy and OHSS rates were similar in women monitored with TVUS alone or TVUS combined with serum E2 monitoring [<a href="#rid17">17</a>]. However, the overall quality of the evidence was low. Given the potential risks and important consequences of OHSS, we continue to suggest monitoring with both TVUS and serum E2.</p><p class="headingAnchor" id="H5388434"><span class="h3">Addition of GnRH agonist or antagonist</span><span class="headingEndMark"> — </span>In the setting of controlled ovarian stimulation with exogenous gonadotropins for IVF, a GnRH agonist or antagonist is also administered to prevent the endogenous luteinizing hormone (LH) surge. hCG is then given to induce final oocyte maturation prior to oocyte retrieval, when follicles are judged to be mature based upon size and serum E2 concentrations. (See  <a class="medical medical_review" href="/z/d/html/7404.html" rel="external">"In vitro fertilization: Overview of clinical issues and questions"</a>.)</p><p>We suggest the use of GnRH antagonists rather than GnRH agonists in women at high risk for OHSS. The use of GnRH agonists is associated with a higher incidence of OHSS, probably due to enhanced follicular recruitment. In contrast, prospective randomized trials and two meta-analyses have reported a lower incidence of OHSS when GnRH antagonists are used, including in women with PCOS [<a href="#rid18">18-25</a>]. However, these same analyses suggest that the use of GnRH antagonists may result in lower pregnancy rates when compared with GnRH agonist therapy.</p><p>The use of GnRH antagonists followed by a GnRH agonist for final oocyte maturation for women donating oocytes is discussed below. (See <a class="local">'GnRH agonist trigger'</a> below.)</p><p class="headingAnchor" id="H1210635783"><span class="h3">Coasting</span><span class="headingEndMark"> — </span>Coasting refers to withholding gonadotropin therapy while continuing pituitary suppression with a GnRH agonist or antagonist until serum E2 levels fall into a range acceptable for hCG administration (eg, associated with a lower OHSS risk). This approach is less common now because of the availability of GnRH antagonists. The larger follicles can continue their growth and maturation when follicle-stimulating hormone (FSH) is stopped; the smaller follicles have a greater FSH requirement and therefore undergo atresia. Although we agree with trying this approach in high-risk cycles, available data are conflicting on its impact on preventing OHSS [<a href="#rid26">26,27</a>].</p><p>We typically start coasting when the dominant follicles are ≥16 mm and serum E2 levels are &gt;3500 pg/mL (12,850 pmol/L) [<a href="#rid26">26</a>]. Once initiated, daily TVUS and serum E2 measurements should be performed; administration of hCG should be withheld until serum E2 falls below 3500 pg/mL (12,850 pmol/L). Coasting for greater than three days (but not up to three days) has a modest adverse effect on pregnancy rates [<a href="#rid28">28</a>]. Therefore, we consider cycle cancellation if E2 levels have not fallen by the fourth day of coasting.</p><p>Based on one review, this approach results in an acceptably low incidence of severe OHSS (&lt;2 percent) with satisfactory fertilization and pregnancy rates (55 to 71 and 37 to 63 percent, respectively) [<a href="#rid29">29</a>].</p><p class="headingAnchor" id="H1210635933"><span class="h3">Withholding hCG (cycle cancellation)</span><span class="headingEndMark"> — </span>Cycle cancellation before administration of exogenous hCG is an effective strategy to prevent OHSS, ie, postponing the treatment cycle until the ovaries have been rendered quiescent [<a href="#rid30">30</a>]. However, cycle cancellation has financial and emotional implications, frustrates both patient and clinician, and results in cancellation of a high percentage of cycles that would not have progressed to clinical OHSS. For patients undergoing agonist cycles at high-risk for severe OHSS, this approach is still a valid and safe alternative that prevents both early and late-onset OHSS forms. As noted, we consider cycle cancellation if E2 levels have not fallen by the fourth day of coasting. (See <a class="local">'Coasting'</a> above.)</p><p class="headingAnchor" id="H87937938"><span class="h3">Pretreatment with metformin</span><span class="headingEndMark"> — </span>We suggest <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a> pretreatment for women with PCOS undergoing IVF. Metformin is an antidiabetic drug that has been extensively investigated in the management of PCOS. Its indications in the management of PCOS have diminished, but it does appear to be useful for pretreatment prior to controlled ovarian stimulation prior to IVF for reducing the risk of OHSS. (See  <a class="medical medical_review" href="/z/d/html/7411.html" rel="external">"Metformin for treatment of the polycystic ovary syndrome"</a>.)</p><p>In two studies, <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a> pretreatment beginning four to five weeks before starting gonadotropin therapy for IVF reduced the risk of OHSS [<a href="#rid31">31,32</a>]. In a meta-analysis of eight trials (n = 798 women), metformin pretreatment decreased the risk of OHSS when compared with placebo (odds ratio [OR] 0.29, 95% CI 0.18-0.49) [<a href="#rid33">33</a>]. The authors calculated that for a woman with a 27 percent risk of having OHSS without metformin, the corresponding chance using metformin treatment would be between 6 and 15 percent. Similar results were seen in a second meta-analysis of 10 trials of over 800 women; metformin pretreatment reduced the risk of OHSS (OR 0.27, 95% CI 0.16-0.46) [<a href="#rid34">34</a>]. No difference in live birth rate was seen with metformin compared with placebo in either meta-analysis [<a href="#rid33">33,34</a>].</p><p class="headingAnchor" id="H1379633520"><span class="h3">Luteal phase support</span><span class="headingEndMark"> — </span>We suggest <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">progesterone</a> regimens over hCG regimens for luteal phase support because they are associated with a lower risk of OHSS (see  <a class="medical medical_review" href="/z/d/html/7404.html" rel="external">"In vitro fertilization: Overview of clinical issues and questions"</a>). Progesterone supplementation is generally initiated on the day of oocyte retrieval or at the time of embryo transfer. An alternative approach has been to administer intermittent, low doses of hCG. In a meta-analysis of seven trials comparing luteal phase progesterone and hCG regimens, the risk of OHSS was significantly lower with progesterone (OR 0.45, 95% CI 0.26-0.79) [<a href="#rid35">35</a>].</p><p class="headingAnchor" id="H779501539"><span class="h2">Ovulatory triggers</span></p><p class="headingAnchor" id="H1379632362"><span class="h3">Low versus standard-dose hCG</span><span class="headingEndMark"> — </span>hCG, which mimics the LH surge, is the standard drug administered for inducing final oocyte maturation. As noted, it is thought to be the pivotal stimulus for OHSS; if withheld, the most severe types of OHSS do not occur  (<a class="graphic graphic_table graphicRef100371" href="/z/d/graphic/100371.html" rel="external">table 1</a>). The effect of hCG is related to its high biological activity, which is six to seven times that of endogenous LH (because of hCG's longer half-life) [<a href="#rid36">36</a>].</p><p>In patients at risk, it had been assumed that <strong>lower</strong> doses of hCG would be associated with lower risks of OHSS by decreasing vascular endothelial growth factor (VEGF) secretion by granulosa cells [<a href="#rid37">37,38</a>]. Evidence to date, including a retrospective study [<a href="#rid39">39</a>], a randomized trial [<a href="#rid40">40</a>], and a systematic review [<a href="#rid41">41</a>], suggests that lowering the dose of hCG to as low as 2500 to 3300 international units results in successful oocyte maturation with similar fertilization and pregnancy rates as doses of 5000 or 10,000 international units. However, it is not clear that the risk of OHSS is reduced, because both the studies and the number of cases are small.</p><p class="headingAnchor" id="H1301594667"><span class="h3">Recombinant LH/recombinant hCG</span><span class="headingEndMark"> — </span>The risk of OHSS appears to be similar with recombinant LH (rLH), recombinant hCG (rhCG) and urinary hCG. Recombinant hCG is a purer preparation of hCG that can be administered subcutaneously, as opposed to urinary hCG which is administered intramuscularly. The risk of OHSS appears to be similar with the two preparations [<a href="#rid42">42</a>]. The biologic half-life of rLH is approximately 10 hours, which is significantly shorter than that of urinary hCG preparations (24 to 36 hours). Therefore, it had been thought that the risk of OHSS may be lower with rLH. However, pooled data from three trials comparing rLH and urinary hCG showed no difference in achieving final follicular maturation in IVF, with similar pregnancy and OHSS rates [<a href="#rid42">42</a>].</p><p class="headingAnchor" id="H119223203"><span class="h3">GnRH agonist trigger</span><span class="headingEndMark"> — </span>In GnRH antagonist cycles, the administration of a GnRH agonist at the end of ovarian stimulation induces an endogenous rise in both LH and FSH concentrations and effectively triggers oocyte maturation [<a href="#rid43">43-47</a>]. This is a useful approach in high-risk patients, preventing both early and late forms of OHSS. In a meta-analysis of 13 studies that assessed fresh autologous IVF cycles and four that assessed donor-recipient cycles, the use of GnRH agonist, when compared with hCG for final oocyte maturation, lowered the risk of OHSS but had a negative impact on live birth rates in the autologous IVF group but not the donor-recipient cycles. We therefore suggest this approach in oocyte donors, a group of healthy young women in whom minimizing OHSS risk is a particularly high priority [<a href="#rid48">48,49</a>]. In IVF patients, we typically use <a class="drug drug_general" data-topicid="9549" href="/z/d/drug information/9549.html" rel="external">leuprolide</a> 0.5 to 1 mg or <a class="drug drug_general" data-topicid="10018" href="/z/d/drug information/10018.html" rel="external">triptorelin</a> 0.1 to 0.2 mg subcutaneously. We agree with the Society of Obstetricians and Gynecologists of Canada who suggest using a GnRH antagonist protocol that includes a GnRH agonist as a substitute for hCG for final oocyte maturation in two settings [<a href="#rid49">49</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Women at high risk for OHSS (development of multiple follicles during ovarian stimulation [&gt;20 follicles over 10 mm])  (<a class="graphic graphic_table graphicRef101682" href="/z/d/graphic/101682.html" rel="external">table 2</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Women undergoing ovarian stimulation who plan to donate oocytes to recipients, or women undergoing fertility preservation cycles (eg, women planning to freeze their oocytes or embryos for future use)</p><p></p><p class="headingAnchor" id="H450078794"><span class="h2">Other interventions</span></p><p class="headingAnchor" id="H119223210"><span class="h3">In vitro oocyte maturation</span><span class="headingEndMark"> — </span>In vitro maturation (IVM) is an <strong>experimental</strong> technique that consists of the in vitro conversion of oocytes at the germinal vesicle stage to oocytes at the metaphase II stage. To be successful, this technology must include nuclear and cytoplasmic maturation of the oocyte and give rise to embryos that have a developmental potential that is similar to embryos obtained from standard IVF or from spontaneously in vivo matured oocytes. Initial studies with IVM resulted in low fertilization rates and suboptimal embryonic quality [<a href="#rid50">50</a>]. However, preliminary studies in women with PCOS suggest that IVM is associated with a lower OHSS rate but also a lower live birth rate than IVF using a GnRH antagonist protocol [<a href="#rid51">51,52</a>]. This technique is not yet used clinically.</p><p class="headingAnchor" id="H119223217"><span class="h3">Embryo cryopreservation</span><span class="headingEndMark"> — </span>Although elective cryopreservation is often considered in cycles at risk for OHSS, its efficacy is not well established. Observational studies [<a href="#rid53">53-55</a>] and one prospective study [<a href="#rid56">56</a>] suggest that elective cryopreservation prevents severe OHSS and that embryo replacement in subsequent natural cycles results in good pregnancy rates. In contrast, in a review of two clinical trials of embryo cryopreservation (one compared with intravenous albumin therapy and one compared with fresh embryo transfer), no differences were observed between groups in the incidence of OHSS, pregnancy rates, or live birth rates [<a href="#rid57">57</a>]. Although data are conflicting, we currently suggest embryo cryopreservation in the following settings:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients at risk for OHSS (&gt;20 follicles larger than 10 mm) who received a GnRH agonist trigger. In these patients, the risk of moderate/severe OHSS is virtually zero, but implantation rates are lower due to impairment of endometrial receptivity. Until luteal support is well established for these cases, cryopreservation of all oocytes/embryos is the best approach.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients at high risk for OHSS who received hCG. Those patients should have their oocytes/embryos cryopreserved to avoid pregnancy and late OHSS. They are still at risk for early OHSS, and <a class="drug drug_general" data-topicid="9384" href="/z/d/drug information/9384.html" rel="external">dopamine</a> agonists should be considered. (See <a class="local">'Dopamine agonists'</a> below.)</p><p></p><p class="headingAnchor" id="H3204502196"><span class="h4">Women with polycystic ovary syndrome</span><span class="headingEndMark"> — </span>Women with PCOS who undergo IVF have lower rates of OHSS with the transfer of frozen rather than fresh embryos. In the largest trial to date, frozen embryo transfer was associated with a lower incidence of OHSS (1 versus 7 percent) compared with fresh embryo transfer [<a href="#rid58">58</a>]. (See  <a class="medical medical_review" href="/z/d/html/7404.html" rel="external">"In vitro fertilization: Overview of clinical issues and questions"</a>.)</p><p class="headingAnchor" id="H119223224"><span class="h3">Intravenous albumin</span><span class="headingEndMark"> — </span>We do not suggest the routine use of intravenous albumin or other volume expanders for the prevention of OHSS. The potential mechanism of action of prophylactic intravenous fluids is to increase plasma oncotic pressure, maintain intravascular volume, and bind to and inactivate ovarian mediators (eg, VEGF) involved in the development of OHSS [<a href="#rid59">59</a>]. In a meta-analysis of eight randomized trials of human intravenous albumin versus placebo, there was only a borderline statistically significant decrease in the incidence of severe OHSS with albumin (OR 0.67, 95% CI 0.45-0.99).</p><p>These results are consistent with two previously published meta-analyses, both of which found no significant benefit of intravenous albumin for reducing the occurrence of severe OHSS in high-risk women [<a href="#rid60">60,61</a>]. In one analysis, pregnancy rates were lower in women receiving albumin compared with no treatment (relative risk [RR] 0.85, 95% CI 0.74-0.98) [<a href="#rid61">61</a>]. Thus, we do not suggest this approach as there is no evidence of benefit and a possible negative impact on pregnancy rates.</p><p>A second volume expander, hydroxyethyl starch, was associated with a reduction in OHSS rates compared with placebo in three trials (OR 0.12, 95% CI 0.04-0.40), but the safety of this product has not been well established.</p><p>Intravenous albumin has also been used for intravenous hydration in the management of severe OHSS. However, available evidence suggests that intravenous albumin provides no additional benefit when compared with crystalloid solutions. (See  <a class="medical medical_review" href="/z/d/html/101383.html" rel="external">"Management of ovarian hyperstimulation syndrome", section on 'Severe and critical OHSS'</a> and  <a class="medical medical_review" href="/z/d/html/1607.html" rel="external">"Treatment of severe hypovolemia or hypovolemic shock in adults", section on 'Normal saline (crystalloid)'</a>.)</p><p class="headingAnchor" id="H119223238"><span class="h3">Dopamine agonists</span><span class="headingEndMark"> — </span>We suggest <a class="drug drug_general" data-topicid="9384" href="/z/d/drug information/9384.html" rel="external">dopamine</a> agonist administration in women at high risk for OHSS who have received hCG. Dopamine agonists inhibit VEGF receptor phosphorylation and thereby decrease vascular permeability, and a number of studies have reported that either dopamine or dopamine agonists reduce the risk of OHSS in women undergoing controlled ovarian stimulation [<a href="#rid62">62-68</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8600" href="/z/d/drug information/8600.html" rel="external">Cabergoline</a> – In a pooled analysis [<a href="#rid69">69</a>] of two placebo-controlled trials of women at high risk of OHSS undergoing ovarian stimulation who were randomly assigned to receive cabergoline (0.5 mg daily beginning on the day of hCG administration [<a href="#rid66">66</a>] or the day of oocyte retrieval [<a href="#rid68">68</a>]) for prevention of OHSS, the rate of moderate OHSS was significantly lower with cabergoline than placebo (20 and 44 percent, respectively). In addition, pregnancy rates do not appear to be compromised by the addition of cabergoline [<a href="#rid67">67</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10227" href="/z/d/drug information/10227.html" rel="external">Quinagolide</a> – Quinagolide, another <a class="drug drug_general" data-topicid="9384" href="/z/d/drug information/9384.html" rel="external">dopamine</a> agonist, appears to reduce the risk of early onset severe OHSS. This was demonstrated in a multicenter trial of 182 IVF patients randomized to receive quinagolide (50, 100, or 200 mcg/day beginning on the day of hCG administration) or placebo [<a href="#rid8">8</a>].</p><p></p><p class="bulletIndent1">The incidence of moderate/severe early-onset OHSS was 23 percent in the placebo group and 12 percent, 13 percent, and 4 percent in the <a class="drug drug_general" data-topicid="10227" href="/z/d/drug information/10227.html" rel="external">quinagolide</a> 50, 100, and 200 mcg/day groups, respectively. The overall rate of moderate/severe OHSS was lower with all quinagolide groups combined compared with the placebo group (OR 0.28, 95% CI 0.09-0.81). No severe OHSS cases were reported in the 200 mcg/day group. Among women who conceived and who were therefore at risk for late-onset OHSS, quinagolide had no beneficial effect.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="10227" href="/z/d/drug information/10227.html" rel="external">Quinagolide</a> is available in some countries, but not the United States, and may be more difficult to tolerate than <a class="drug drug_general" data-topicid="8600" href="/z/d/drug information/8600.html" rel="external">cabergoline</a>.</p><p></p><p class="headingAnchor" id="H1379633491"><span class="h3">Low-dose aspirin</span><span class="headingEndMark"> — </span>Two studies suggest that low-dose <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> may be associated with a lower risk of OHSS [<a href="#rid70">70,71</a>]. However, we do not suggest its use at this time.</p><p class="headingAnchor" id="H2206676482"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/117617.html" rel="external">"Society guideline links: Ovarian hyperstimulation syndrome"</a>.)</p><p class="headingAnchor" id="H119224504"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>The keys to preventing ovarian hyperstimulation syndrome (OHSS) are to identify the potential risk for the individual patient and to plan appropriate strategies to avoid its occurrence  (<a class="graphic graphic_table graphicRef101682" href="/z/d/graphic/101682.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Risk factors include a previous episode of OHSS or exuberant ovarian response to gonadotropins, and polycystic ovarian syndrome (PCOS)  (<a class="graphic graphic_table graphicRef101682" href="/z/d/graphic/101682.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/z/d/html/7401.html" rel="external">"Pathogenesis, clinical manifestations, and diagnosis of ovarian hyperstimulation syndrome", section on 'Risk factors'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We suggest the use of individualized ovarian stimulation regimens, using the minimum dose and duration of gonadotropin therapy necessary to achieve the treatment goal (particularly in those at risk for OHSS) (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Ovarian stimulation protocol'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the setting of controlled ovarian stimulation with exogenous gonadotropins for IVF, a GnRH agonist or antagonist is also administered to prevent the endogenous luteinizing hormone (LH) surge. For women at high risk for OHSS, we suggest the use of GnRH antagonists rather than GnRH agonists (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). (See <a class="local">'Addition of GnRH agonist or antagonist'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We suggest <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a> pretreatment for women with PCOS undergoing IVF (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Pretreatment with metformin'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>During gonadotropin therapy, indicators of increasing OHSS risk that require treatment modification include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Serum estradiol (E2) concentration &gt;3500 pg/mL (12,850 pmol/L).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Development of many intermediate sized follicles (&gt;20 follicles over 10 mm diameter).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Treatment modification options in high-risk cycles to lower OHSS risk include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Withholding gonadotropin administration (coasting) until serum E2 falls below 3500 pg/mL (12,850 pmol/L). (See <a class="local">'Coasting'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Using an alternative to standard-dose human chorionic gonadotropin (hCG) for final oocyte maturation (GnRH agonist). (See <a class="local">'Ovulatory triggers'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Administration of <a class="drug drug_general" data-topicid="9384" href="/z/d/drug information/9384.html" rel="external">dopamine</a> agonist if hCG has already been given as the ovulatory trigger.</p><p></p><p class="headingAnchor" id="H872577119"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The editorial staff at UpToDate would like to acknowledge Bruno Lunenfeld, MD and the late Vaclav Insler, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Golan A, Ron-el R, Herman A, et al. Ovarian hyperstimulation syndrome: an update review. Obstet Gynecol Surv 1989; 44:430.</a></li><li><a class="nounderline abstract_t">Whelan JG 3rd, Vlahos NF. The ovarian hyperstimulation syndrome. Fertil Steril 2000; 73:883.</a></li><li><a class="nounderline abstract_t">Lyons CA, Wheeler CA, Frishman GN, et al. Early and late presentation of the ovarian hyperstimulation syndrome: two distinct entities with different risk factors. Hum Reprod 1994; 9:792.</a></li><li class="breakAll">Rizk B. Ovarian hyperstimulation syndrome. In: Progress in obstetrics and gynecology, Studd J (Ed), Churchill and Livingstone, Edinburgh 1997. Vol 11, p.311.</li><li class="breakAll">Rizk B. Prevention of ovarian hypertimulation syndrome: the ten commandments. Presented at the European Society of Human Reproduction and Embryology Symposium, Tel Aviv, Israel, pp. 1-2.</li><li><a class="nounderline abstract_t">Serour GI, Aboulghar M, Mansour R, et al. Complications of medically assisted conception in 3,500 cycles. Fertil Steril 1998; 70:638.</a></li><li><a class="nounderline abstract_t">Ovarian Stimulation TEGGO, Bosch E, Broer S, et al. ESHRE guideline: ovarian stimulation for IVF/ICSI†. Hum Reprod Open 2020; 2020:hoaa009.</a></li><li><a class="nounderline abstract_t">Busso C, Fernández-Sánchez M, García-Velasco JA, et al. The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial. Hum Reprod 2010; 25:995.</a></li><li><a class="nounderline abstract_t">Fauser BC, Van Heusden AM. Manipulation of human ovarian function: physiological concepts and clinical consequences. Endocr Rev 1997; 18:71.</a></li><li><a class="nounderline abstract_t">Homburg R, Insler V. Ovulation induction in perspective. Hum Reprod Update 2002; 8:449.</a></li><li><a class="nounderline abstract_t">Olivennes F, Howies CM, Borini A, et al. Individualizing FSH dose for assisted reproduction using a novel algorithm: the CONSORT study. Reprod Biomed Online 2011; 22 Suppl 1:S73.</a></li><li><a class="nounderline abstract_t">Bayram N, van Wely M, Vandekerckhove P, et al. Pulsatile luteinising hormone releasing hormone for ovulation induction in subfertility associated with polycystic ovary syndrome. Cochrane Database Syst Rev 2000; :CD000412.</a></li><li class="breakAll">Daya Salim, Gunby Joanne L. Recombinant versus urinary follicle stimulating hormone for ovarian stimulation in assisted reproduction cycles. Cochrane Database of Systematic Reviews. In: The Cochrane Library, Issue 3, Art. No. CD002810. DOI: 0.1002/14651858.CD002810.pub4</li><li class="breakAll">Westergaard Lars W, Bossuyt Patrick MM, Van der Veen Fulco, van Wely Madelon. Human menopausal gonadotropin versus recombinant follicle stimulation hormone for ovarian stimulation in assisted reproductive cycles. Cochrane Database of Systematic Reviews. In: The Cochrane Library, Issue 11, Art. No. CD003973.</li><li><a class="nounderline abstract_t">Kahnberg A, Enskog A, Brännström M, et al. Prediction of ovarian hyperstimulation syndrome in women undergoing in vitro fertilization. Acta Obstet Gynecol Scand 2009; 88:1373.</a></li><li><a class="nounderline abstract_t">D'Angelo A, Davies R, Salah E, et al. Value of the serum estradiol level for preventing ovarian hyperstimulation syndrome: a retrospective case control study. Fertil Steril 2004; 81:332.</a></li><li><a class="nounderline abstract_t">Kwan I, Bhattacharya S, Kang A, Woolner A. Monitoring of stimulated cycles in assisted reproduction (IVF and ICSI). Cochrane Database Syst Rev 2014; :CD005289.</a></li><li><a class="nounderline abstract_t">A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). The ganirelix dose-finding study group. Hum Reprod 1998; 13:3023.</a></li><li><a class="nounderline abstract_t">Albano C, Felberbaum RE, Smitz J, et al. Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group. Hum Reprod 2000; 15:526.</a></li><li><a class="nounderline abstract_t">Olivennes F, Belaisch-Allart J, Emperaire JC, et al. Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin). Fertil Steril 2000; 73:314.</a></li><li><a class="nounderline abstract_t">Borm G, Mannaerts B. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group. Hum Reprod 2000; 15:1490.</a></li><li><a class="nounderline abstract_t">European and Middle East Orgalutran Study Group. Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. Hum Reprod 2001; 16:644.</a></li><li><a class="nounderline abstract_t">Ragni G, Vegetti W, Riccaboni A, et al. Comparison of GnRH agonists and antagonists in assisted reproduction cycles of patients at high risk of ovarian hyperstimulation syndrome. Hum Reprod 2005; 20:2421.</a></li><li><a class="nounderline abstract_t">Al-Inany HG, Abou-Setta AM, Aboulghar M. Gonadotrophin-releasing hormone antagonists for assisted conception: a Cochrane review. Reprod Biomed Online 2007; 14:640.</a></li><li><a class="nounderline abstract_t">Lin H, Li Y, Li L, et al. Is a GnRH antagonist protocol better in PCOS patients? A meta-analysis of RCTs. PLoS One 2014; 9:e91796.</a></li><li><a class="nounderline abstract_t">Delvigne A, Rozenberg S. A qualitative systematic review of coasting, a procedure to avoid ovarian hyperstimulation syndrome in IVF patients. Hum Reprod Update 2002; 8:291.</a></li><li><a class="nounderline abstract_t">D'Angelo A, Brown J, Amso NN. Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev 2011; :CD002811.</a></li><li><a class="nounderline abstract_t">Mansour R, Aboulghar M, Serour G, et al. Criteria of a successful coasting protocol for the prevention of severe ovarian hyperstimulation syndrome. Hum Reprod 2005; 20:3167.</a></li><li><a class="nounderline abstract_t">Levinsohn-Tavor O, Friedler S, Schachter M, et al. Coasting-what is the best formula? Hum Reprod 2003; 18:937.</a></li><li><a class="nounderline abstract_t">Rizk B, Aboulghar M. Modern management of ovarian hyperstimulation syndrome. Hum Reprod 1991; 6:1082.</a></li><li><a class="nounderline abstract_t">Tang T, Glanville J, Orsi N, et al. The use of metformin for women with PCOS undergoing IVF treatment. Hum Reprod 2006; 21:1416.</a></li><li><a class="nounderline abstract_t">Khattab S, Fotouh IA, Mohesn IA, et al. Use of metformin for prevention of ovarian hyperstimulation syndrome: a novel approach. Reprod Biomed Online 2006; 13:194.</a></li><li><a class="nounderline abstract_t">Tso LO, Costello MF, Albuquerque LE, et al. Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. Cochrane Database Syst Rev 2014; :CD006105.</a></li><li><a class="nounderline abstract_t">Palomba S, Falbo A, La Sala GB. Effects of metformin in women with polycystic ovary syndrome treated with gonadotrophins for in vitro fertilisation and intracytoplasmic sperm injection cycles: a systematic review and meta-analysis of randomised controlled trials. BJOG 2013; 120:267.</a></li><li><a class="nounderline abstract_t">van der Linden M, Buckingham K, Farquhar C, et al. Luteal phase support for assisted reproduction cycles. Cochrane Database Syst Rev 2011; :CD009154.</a></li><li><a class="nounderline abstract_t">Yen SS, Llerena O, Little B, Pearson OH. Disappearance rates of endogenous luteinizing hormone and chorionic gonadotropin in man. J Clin Endocrinol Metab 1968; 28:1763.</a></li><li><a class="nounderline abstract_t">Agrawal R, Conway G, Sladkevicius P, et al. Serum vascular endothelial growth factor and Doppler blood flow velocities in in vitro fertilization: relevance to ovarian hyperstimulation syndrome and polycystic ovaries. Fertil Steril 1998; 70:651.</a></li><li><a class="nounderline abstract_t">Pellicer A, Albert C, Mercader A, et al. The pathogenesis of ovarian hyperstimulation syndrome: in vivo studies investigating the role of interleukin-1beta, interleukin-6, and vascular endothelial growth factor. Fertil Steril 1999; 71:482.</a></li><li><a class="nounderline abstract_t">Schmidt DW, Maier DB, Nulsen JC, Benadiva CA. Reducing the dose of human chorionic gonadotropin in high responders does not affect the outcomes of in vitro fertilization. Fertil Steril 2004; 82:841.</a></li><li><a class="nounderline abstract_t">Kolibianakis EM, Papanikolaou EG, Tournaye H, et al. Triggering final oocyte maturation using different doses of human chorionic gonadotropin: a randomized pilot study in patients with polycystic ovary syndrome treated with gonadotropin-releasing hormone antagonists and recombinant follicle-stimulating hormone. Fertil Steril 2007; 88:1382.</a></li><li><a class="nounderline abstract_t">Tsoumpou I, Muglu J, Gelbaya TA, Nardo LG. Symposium: Update on prediction and management of OHSS. Optimal dose of HCG for final oocyte maturation in IVF cycles: absence of evidence? Reprod Biomed Online 2009; 19:52.</a></li><li><a class="nounderline abstract_t">Youssef MA, Al-Inany HG, Aboulghar M, et al. Recombinant versus urinary human chorionic gonadotrophin for final oocyte maturation triggering in IVF and ICSI cycles. Cochrane Database Syst Rev 2011; :CD003719.</a></li><li><a class="nounderline abstract_t">Griesinger G, Diedrich K, Devroey P, Kolibianakis EM. GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis. Hum Reprod Update 2006; 12:159.</a></li><li><a class="nounderline abstract_t">Acevedo B, Gomez-Palomares JL, Ricciarelli E, Hernández ER. Triggering ovulation with gonadotropin-releasing hormone agonists does not compromise embryo implantation rates. Fertil Steril 2006; 86:1682.</a></li><li><a class="nounderline abstract_t">Babayof R, Margalioth EJ, Huleihel M, et al. Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial. Hum Reprod 2006; 21:1260.</a></li><li><a class="nounderline abstract_t">Engmann L, Siano L, Schmidt D, et al. GnRH agonist to induce oocyte maturation during IVF in patients at high risk of OHSS. Reprod Biomed Online 2006; 13:639.</a></li><li><a class="nounderline abstract_t">Youssef MA, Van der Veen F, Al-Inany HG, et al. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology. Cochrane Database Syst Rev 2014; :CD008046.</a></li><li><a class="nounderline abstract_t">Melo M, Busso CE, Bellver J, et al. GnRH agonist versus recombinant HCG in an oocyte donation programme: a randomized, prospective, controlled, assessor-blind study. Reprod Biomed Online 2009; 19:486.</a></li><li><a class="nounderline abstract_t">Corbett S, Shmorgun D, Claman P, et al. The prevention of ovarian hyperstimulation syndrome. J Obstet Gynaecol Can 2014; 36:1024.</a></li><li><a class="nounderline abstract_t">Grøndahl C. Oocyte maturation. Basic and clinical aspects of in vitro maturation (IVM) with special emphasis of the role of FF-MAS. Dan Med Bull 2008; 55:1.</a></li><li><a class="nounderline abstract_t">Das M, Son WY, Buckett W, et al. In-vitro maturation versus IVF with GnRH antagonist for women with polycystic ovary syndrome: treatment outcome and rates of ovarian hyperstimulation syndrome. Reprod Biomed Online 2014; 29:545.</a></li><li><a class="nounderline abstract_t">Shavit T, Ellenbogen A, Michaeli M, et al. In-vitro maturation of oocytes vs in-vitro fertilization with a gonadotropin-releasing hormone antagonist for women with polycystic ovarian syndrome: can superiority be defined? Eur J Obstet Gynecol Reprod Biol 2014; 179:46.</a></li><li><a class="nounderline abstract_t">Pattinson HA, Hignett M, Dunphy BC, Fleetham JA. Outcome of thaw embryo transfer after cryopreservation of all embryos in patients at risk of ovarian hyperstimulation syndrome. Fertil Steril 1994; 62:1192.</a></li><li><a class="nounderline abstract_t">Tiitinen A, Husa LM, Tulppala M, et al. The effect of cryopreservation in prevention of ovarian hyperstimulation syndrome. Br J Obstet Gynaecol 1995; 102:326.</a></li><li><a class="nounderline abstract_t">Queenan JT Jr, Veeck LL, Toner JP, et al. Cryopreservation of all prezygotes in patients at risk of severe hyperstimulation does not eliminate the syndrome, but the chances of pregnancy are excellent with subsequent frozen-thaw transfers. Hum Reprod 1997; 12:1573.</a></li><li><a class="nounderline abstract_t">Ferraretti AP, Gianaroli L, Magli C, et al. Elective cryopreservation of all pronucleate embryos in women at risk of ovarian hyperstimulation syndrome: efficiency and safety. Hum Reprod 1999; 14:1457.</a></li><li><a class="nounderline abstract_t">D'Angelo A, Amso N. Embryo freezing for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev 2007; :CD002806.</a></li><li><a class="nounderline abstract_t">Chen ZJ, Shi Y, Sun Y, et al. Fresh versus Frozen Embryos for Infertility in the Polycystic Ovary Syndrome. N Engl J Med 2016; 375:523.</a></li><li><a class="nounderline abstract_t">Youssef MA, Al-Inany HG, Evers JL, Aboulghar M. Intra-venous fluids for the prevention of severe ovarian hyperstimulation syndrome. Cochrane Database Syst Rev 2011; :CD001302.</a></li><li><a class="nounderline abstract_t">Venetis CA, Kolibianakis EM, Toulis KA, et al. Intravenous albumin administration for the prevention of severe ovarian hyperstimulation syndrome: a systematic review and metaanalysis. Fertil Steril 2011; 95:188.</a></li><li><a class="nounderline abstract_t">Jee BC, Suh CS, Kim YB, et al. Administration of intravenous albumin around the time of oocyte retrieval reduces pregnancy rate without preventing ovarian hyperstimulation syndrome: a systematic review and meta-analysis. Gynecol Obstet Invest 2010; 70:47.</a></li><li><a class="nounderline abstract_t">Ferraretti AP, Gianaroli L, Diotallevi L, et al. Dopamine treatment for severe ovarian hyperstimulation syndrome. Hum Reprod 1992; 7:180.</a></li><li><a class="nounderline abstract_t">Tsunoda T, Shibahara H, Hirano Y, et al. Treatment for ovarian hyperstimulation syndrome using an oral dopamine prodrug, docarpamine. Gynecol Endocrinol 2003; 17:281.</a></li><li><a class="nounderline abstract_t">Manno M, Tomei F, Marchesan E, Adamo V. Cabergoline: a safe, easy, cheap, and effective drug for prevention/treatment of ovarian hyperstimulation syndrome? Eur J Obstet Gynecol Reprod Biol 2005; 122:127.</a></li><li><a class="nounderline abstract_t">Papaleo E, Doldi N, De Santis L, et al. Cabergoline influences ovarian stimulation in hyperprolactinaemic patients with polycystic ovary syndrome. Hum Reprod 2001; 16:2263.</a></li><li><a class="nounderline abstract_t">Alvarez C, Martí-Bonmatí L, Novella-Maestre E, et al. Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. J Clin Endocrinol Metab 2007; 92:2931.</a></li><li><a class="nounderline abstract_t">Alvarez C, Alonso-Muriel I, García G, et al. Implantation is apparently unaffected by the dopamine agonist Cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study. Hum Reprod 2007; 22:3210.</a></li><li><a class="nounderline abstract_t">Carizza C, Abdelmassih V, Abdelmassih S, et al. Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study. Reprod Biomed Online 2008; 17:751.</a></li><li><a class="nounderline abstract_t">Tang H, Hunter T, Hu Y, et al. Cabergoline for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev 2012; :CD008605.</a></li><li><a class="nounderline abstract_t">Moini A, Zafarani F, Haddadian S, et al. Effect of low-dose aspirin therapy on implantation rate in women undergoing in-vitro fertilization cycles. Saudi Med J 2007; 28:732.</a></li><li><a class="nounderline abstract_t">Várnagy A, Bódis J, Mánfai Z, et al. Low-dose aspirin therapy to prevent ovarian hyperstimulation syndrome. Fertil Steril 2010; 93:2281.</a></li></ol></div><div id="topicVersionRevision">Topic 7412 Version 14.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2660037" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Ovarian hyperstimulation syndrome: an update review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10785212" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The ovarian hyperstimulation syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7929724" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Early and late presentation of the ovarian hyperstimulation syndrome: two distinct entities with different risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7929724" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Early and late presentation of the ovarian hyperstimulation syndrome: two distinct entities with different risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7929724" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Early and late presentation of the ovarian hyperstimulation syndrome: two distinct entities with different risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9797090" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Complications of medically assisted conception in 3,500 cycles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32395637" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : ESHRE guideline: ovarian stimulation for IVF/ICSI†.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20139430" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9034787" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Manipulation of human ovarian function: physiological concepts and clinical consequences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12398225" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Ovulation induction in perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21575853" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Individualizing FSH dose for assisted reproduction using a novel algorithm: the CONSORT study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10796718" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Pulsatile luteinising hormone releasing hormone for ovulation induction in subfertility associated with polycystic ovary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10796718" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Pulsatile luteinising hormone releasing hormone for ovulation induction in subfertility associated with polycystic ovary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10796718" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Pulsatile luteinising hormone releasing hormone for ovulation induction in subfertility associated with polycystic ovary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19878052" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Prediction of ovarian hyperstimulation syndrome in women undergoing in vitro fertilization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14967369" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Value of the serum estradiol level for preventing ovarian hyperstimulation syndrome: a retrospective case control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25150465" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Monitoring of stimulated cycles in assisted reproduction (IVF and ICSI).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9853849" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). The ganirelix dose-finding study group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10686191" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10685535" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10875855" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11278211" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15890731" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Comparison of GnRH agonists and antagonists in assisted reproduction cycles of patients at high risk of ovarian hyperstimulation syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17509210" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Gonadotrophin-releasing hormone antagonists for assisted conception: a Cochrane review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24642641" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Is a GnRH antagonist protocol better in PCOS patients? A meta-analysis of RCTs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12078839" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : A qualitative systematic review of coasting, a procedure to avoid ovarian hyperstimulation syndrome in IVF patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21678336" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16006465" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Criteria of a successful coasting protocol for the prevention of severe ovarian hyperstimulation syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12721165" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Coasting-what is the best formula?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1806565" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Modern management of ovarian hyperstimulation syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16501038" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The use of metformin for women with PCOS undergoing IVF treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16895631" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Use of metformin for prevention of ovarian hyperstimulation syndrome: a novel approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25406011" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23194199" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Effects of metformin in women with polycystic ovary syndrome treated with gonadotrophins for in vitro fertilisation and intracytoplasmic sperm injection cycles: a systematic review and meta-analysis of randomised controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21975790" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Luteal phase support for assisted reproduction cycles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5699949" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Disappearance rates of endogenous luteinizing hormone and chorionic gonadotropin in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9797093" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Serum vascular endothelial growth factor and Doppler blood flow velocities in in vitro fertilization: relevance to ovarian hyperstimulation syndrome and polycystic ovaries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10065786" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : The pathogenesis of ovarian hyperstimulation syndrome: in vivo studies investigating the role of interleukin-1beta, interleukin-6, and vascular endothelial growth factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15482757" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Reducing the dose of human chorionic gonadotropin in high responders does not affect the outcomes of in vitro fertilization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17445806" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Triggering final oocyte maturation using different doses of human chorionic gonadotropin: a randomized pilot study in patients with polycystic ovary syndrome treated with gonadotropin-releasing hormone antagonists and recombinant follicle-stimulating hormone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19573290" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Symposium: Update on prediction and management of OHSS. Optimal dose of HCG for final oocyte maturation in IVF cycles: absence of evidence?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21491386" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Recombinant versus urinary human chorionic gonadotrophin for final oocyte maturation triggering in IVF and ICSI cycles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16254001" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17074344" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Triggering ovulation with gonadotropin-releasing hormone agonists does not compromise embryo implantation rates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16439507" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17169172" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : GnRH agonist to induce oocyte maturation during IVF in patients at high risk of OHSS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25358904" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19909588" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : GnRH agonist versus recombinant HCG in an oocyte donation programme: a randomized, prospective, controlled, assessor-blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25574681" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : The prevention of ovarian hyperstimulation syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18321442" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Oocyte maturation. Basic and clinical aspects of in vitro maturation (IVM) with special emphasis of the role of FF-MAS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25262236" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : In-vitro maturation versus IVF with GnRH antagonist for women with polycystic ovary syndrome: treatment outcome and rates of ovarian hyperstimulation syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24965979" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : In-vitro maturation of oocytes vs in-vitro fertilization with a gonadotropin-releasing hormone antagonist for women with polycystic ovarian syndrome: can superiority be defined?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7957983" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Outcome of thaw embryo transfer after cryopreservation of all embryos in patients at risk of ovarian hyperstimulation syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7612517" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : The effect of cryopreservation in prevention of ovarian hyperstimulation syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9262299" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Cryopreservation of all prezygotes in patients at risk of severe hyperstimulation does not eliminate the syndrome, but the chances of pregnancy are excellent with subsequent frozen-thaw transfers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10357958" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Elective cryopreservation of all pronucleate embryos in women at risk of ovarian hyperstimulation syndrome: efficiency and safety.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17636707" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Embryo freezing for preventing ovarian hyperstimulation syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27509101" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Fresh versus Frozen Embryos for Infertility in the Polycystic Ovary Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21328249" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Intra-venous fluids for the prevention of severe ovarian hyperstimulation syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20579987" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Intravenous albumin administration for the prevention of severe ovarian hyperstimulation syndrome: a systematic review and metaanalysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20173327" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Administration of intravenous albumin around the time of oocyte retrieval reduces pregnancy rate without preventing ovarian hyperstimulation syndrome: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1577929" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Dopamine treatment for severe ovarian hyperstimulation syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14503971" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Treatment for ovarian hyperstimulation syndrome using an oral dopamine prodrug, docarpamine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16154051" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Cabergoline: a safe, easy, cheap, and effective drug for prevention/treatment of ovarian hyperstimulation syndrome?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11679501" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Cabergoline influences ovarian stimulation in hyperprolactinaemic patients with polycystic ovary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17456571" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17921134" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Implantation is apparently unaffected by the dopamine agonist Cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19079957" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22336848" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Cabergoline for preventing ovarian hyperstimulation syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17457441" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Effect of low-dose aspirin therapy on implantation rate in women undergoing in-vitro fertilization cycles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19261278" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Low-dose aspirin therapy to prevent ovarian hyperstimulation syndrome.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
